Phathom Pharmaceuticals (PHAT) Return on Capital Employed (2019 - 2026)
Phathom Pharmaceuticals (PHAT) reported Return on Capital Employed of 61.49% for Q1 2026, up 4772.0% year-over-year from 1.26% in Q1 2025, and up 54.77% quarter-over-quarter from 135.96% in Q4 2025.
Phathom Pharmaceuticals (PHAT) Return on Capital Employed (2019 - 2026) Analysis & Trends
Phathom Pharmaceuticals (PHAT) has 8 years of Return on Capital Employed data on file, last reported at 61.49% in Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 61.49%, up 4772.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 61.49% (up 4772.0% YoY), and the FY2025 annual result was 85.7%, up 371.0% from the prior year.
- Return on Capital Employed climbed to 61.49% in Q1 2026 per PHAT's latest filing, from 135.96% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 58.37% in Q4 2023 and troughed at 149.12% in Q2 2025.
- A 5-year average of 96.25% and a median of 93.29% in 2022 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed soared 5697 bps in 2024, then plunged 6223 bps in 2025.
- A 5-year view of Return on Capital Employed shows it stood at 109.74% in 2022, then jumped by 47 bps to 58.37% in 2023, then slumped by 60 bps to 93.44% in 2024, then slumped by 46 bps to 135.96% in 2025, then surged by 55 bps to 61.49% in 2026.
- Business Quant data shows PHAT's Return on Capital Employed at 61.49% in Q1 2026, 135.96% in Q4 2025, and 140.32% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Phathom Pharmaceuticals | 895.99 Mn | 712.23 Mn | 46.31 Mn | -61.49% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -61.49% |
| Dec 31, 2025 | -135.96% |
| Sep 30, 2025 | -140.32% |
| Jun 30, 2025 | -149.12% |
| Mar 31, 2025 | -109.21% |
| Dec 31, 2024 | -93.44% |
| Sep 30, 2024 | -100.00% |
| Jun 30, 2024 | -86.89% |
| Mar 31, 2024 | -60.63% |
| Dec 31, 2023 | -58.37% |
| Sep 30, 2023 | -63.46% |
| Jun 30, 2023 | -82.50% |
| Mar 31, 2023 | -117.61% |
| Dec 31, 2022 | -109.74% |
| Sep 30, 2022 | -85.93% |
| Jun 30, 2022 | -93.29% |
| Mar 31, 2022 | -88.32% |
| Dec 31, 2021 | -71.10% |
| Sep 30, 2021 | -79.77% |
| Jun 30, 2021 | -80.78% |